Berman Capital Advisors’s Immunogen Inc IMGN Stock Holding History

Berman Capital Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$0	Hold	32	–	–	﹤0.01%	2271
2021 Q2	$0	Buy	+32	New	+$223	﹤0.01%	2088

Other funds holding IMGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Berman Capital Advisors's IMGN Position: Q3 2021 in Review

Berman Capital Advisors held its Immunogen Inc (IMGN) position steady in Q3 2021 at 32 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2271.

Berman Capital Advisors first reported a position in IMGN in Q2 2021 and has held it in 2 quarters since. 217 funds tracked by Wall St. Rank hold IMGN as of Q3 2021.

Berman Capital Advisors held 32 shares of Immunogen Inc worth $0 as of Q3 2021.
Berman Capital Advisors left its Immunogen Inc share count unchanged in Q3 2021.
Immunogen Inc made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2271 holding.
Berman Capital Advisors first reported a position in Immunogen Inc in Q2 2021 and has held it in 2 quarters since.
217 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.